{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:01:21Z","timestamp":1789556481522,"version":"build-2803163510"},"reference-count":112,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL095524"],"award-info":[{"award-number":["HL095524"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK051870"],"award-info":[{"award-number":["DK051870"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,15]]},"DOI":"10.1093\/hmg\/ddz026","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T23:13:39Z","timestamp":1549408419000},"page":"1982-2000","source":"Crossref","is-referenced-by-count":27,"title":["HDAC inhibitors rescue multiple disease-causing CFTR variants"],"prefix":"10.1093","volume":"28","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Angl\u00e8s","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, Scripps Research, North Torrey Pines Rd, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren M","family":"Hutt","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Scripps Research, North Torrey Pines Rd, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E","family":"Balch","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Scripps Research, North Torrey Pines Rd, La Jolla, CA, USA"},{"name":"Skaggs Institute of Chemical Biology, North Torrey Pines Rd, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,7]]},"reference":[{"key":"2019060412153491000_ref1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jcf.2015.09.006","article-title":"Hallmarks of therapeutic management of the cystic fibrosis functional landscape","volume":"14","author":"Amaral","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"2019060412153491000_ref2","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.celrep.2018.07.059","article-title":"Bridging genomics to phenomics at atomic resolution through variation spatial profiling","volume":"24","author":"Wang","year":"2018","journal-title":"Cell Rep."},{"key":"2019060412153491000_ref3","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1128\/AAC.01011-06","article-title":"Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr\u2212\/\u2212 mice","volume":"51","author":"Hoffmann","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"2019060412153491000_ref4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: from molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"2019060412153491000_ref5","doi-asserted-by":"crossref","first-page":"15739","DOI":"10.1074\/jbc.272.25.15739","article-title":"Localization and suppression of a kinetic defect in cystic fibrosis transmembrane conductance regulator folding","volume":"272","author":"Qu","year":"1997","journal-title":"J. Biol. Chem."},{"key":"2019060412153491000_ref6","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ng.2745","article-title":"Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene","volume":"45","author":"Sosnay","year":"2013","journal-title":"Nat. Genet."},{"key":"2019060412153491000_ref7","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1091\/mbc.e06-05-0458","article-title":"Small heat-shock proteins select deltaF508-CFTR for endoplasmic reticulum-associated degradation","volume":"18","author":"Ahner","year":"2007","journal-title":"Mol. Biol. Cell"},{"key":"2019060412153491000_ref8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ceb.2009.04.006","article-title":"Substrate-specific mediators of ER associated degradation (ERAD)","volume":"21","author":"Brodsky","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"key":"2019060412153491000_ref9","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1074\/jbc.M115.685628","article-title":"Non-native conformers of cystic fibrosis transmembrane conductance regulator NBD1 are recognized by Hsp27 and conjugated to SUMO-2 for degradation","volume":"291","author":"Gong","year":"2016","journal-title":"J. Biol. Chem"},{"key":"2019060412153491000_ref10","doi-asserted-by":"crossref","first-page":"19158","DOI":"10.1074\/jbc.M111.297580","article-title":"Human heat shock protein 105\/110kDa (Hsp105\/110) regulates biogenesis and quality control of misfolded cystic fibrosis transmembrane conductance regulator at multiple levels","volume":"287","author":"Saxena","year":"2012","journal-title":"J. Biol. Chem."},{"key":"2019060412153491000_ref11","doi-asserted-by":"crossref","first-page":"36856","DOI":"10.1074\/jbc.M607085200","article-title":"Derlin-1 promotes the efficient degradation of the cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR folding mutants","volume":"281","author":"Sun","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"Suppl. 1","key":"2019060412153491000_ref12","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1186\/1471-2091-8-S1-S11","article-title":"The role of the UPS in cystic fibrosis","volume":"8","author":"Turnbull","year":"2007","journal-title":"BMC Biochem"},{"key":"2019060412153491000_ref13","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nrm2546","article-title":"One step at a time: endoplasmic reticulum-associated degradation","volume":"9","author":"Vembar","year":"2008","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"2019060412153491000_ref14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"2019060412153491000_ref15","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1091\/mbc.e13-05-0240","article-title":"VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1","volume":"24","author":"Ren","year":"2013","journal-title":"Mol. Biol. Cell"},{"key":"2019060412153491000_ref16","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2019060412153491000_ref17","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2019060412153491000_ref18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Van Goor","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"2019060412153491000_ref19","doi-asserted-by":"crossref","first-page":"246ra297","DOI":"10.1126\/scitranslmed.3008889","article-title":"Some gating potentiators, including VX-770, diminish DeltaF508-CFTR functional expression","volume":"6","author":"Veit","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"2019060412153491000_ref20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2174\/138161208783885353","article-title":"Chemical origins of isoform selectivity in histone deacetylase inhibitors","volume":"14","author":"Butler","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"2019060412153491000_ref21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1517\/13543784.17.2.169","article-title":"Histone deacetylase inhibitors: possible implications for neurodegenerative disorders","volume":"17","author":"Hahnen","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2019060412153491000_ref22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nbt1272","article-title":"Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug","volume":"25","author":"Marks","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"2019060412153491000_ref23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2183\/pjab.93.019","article-title":"Chemical and structural biology of protein lysine deacetylases","volume":"93","author":"Yoshida","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"2019060412153491000_ref24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/23808993.2017.1284557","article-title":"The role of epigenomics in personalized medicine","volume":"2","author":"Kronfol","year":"2017","journal-title":"Expert Rev. Precis. Med. Drug Dev."},{"key":"2019060412153491000_ref25","doi-asserted-by":"crossref","first-page":"aac4354","DOI":"10.1126\/science.aac4354","article-title":"In vivo aspects of protein folding and quality control","volume":"353","author":"Balchin","year":"2016","journal-title":"Science"},{"key":"2019060412153491000_ref26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrm3542","article-title":"Diversity in the origins of proteostasis networks\u2014a driver for protein function in evolution","volume":"14","author":"Powers","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2019060412153491000_ref27","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.1141448","article-title":"Adapting proteostasis for disease intervention","volume":"319","author":"Balch","year":"2008","journal-title":"Science."},{"key":"2019060412153491000_ref28","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1083\/jcb.201612111","article-title":"Shaping proteostasis at the cellular, tissue, and organismal level","volume":"216","author":"Sala","year":"2017","journal-title":"J. Cell Biol"},{"key":"2019060412153491000_ref29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev-biochem-060614-033955","article-title":"The biology of proteostasis in aging and disease","volume":"84","author":"Labbadia","year":"2015","journal-title":"Annu. Rev. Biochem."},{"key":"2019060412153491000_ref30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1083\/jcb.201709072","article-title":"Pathways of cellular proteostasis in aging and disease","volume":"217","author":"Klaips","year":"2018","journal-title":"J. Cell Biol."},{"key":"2019060412153491000_ref31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-biochem-061516-044518","article-title":"Protein misfolding diseases","volume":"86","author":"Hartl","year":"2017","journal-title":"Annu. Rev. Biochem."},{"key":"2019060412153491000_ref32","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.tcb.2017.08.002","article-title":"Rethinking HSF1 in stress, development, and organismal health","volume":"27","author":"Li","year":"2017","journal-title":"Trends Cell Biol."},{"key":"2019060412153491000_ref33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.molcel.2017.05.031","article-title":"The UPR(ER): sensor and coordinator of organismal homeostasis","volume":"66","author":"Frakes","year":"2017","journal-title":"Mol. Cell"},{"key":"2019060412153491000_ref34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1517\/14728222.2013.756471","article-title":"Targeting endoplasmic reticulum stress in metabolic disease","volume":"17","author":"Cao","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"key":"2019060412153491000_ref35","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2016.05.013","article-title":"The aging epigenome","volume":"62","author":"Booth","year":"2016","journal-title":"Mol. Cell"},{"key":"2019060412153491000_ref36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/518313a","article-title":"Presenting the epigenome roadmap","volume":"518","author":"Skipper","year":"2015","journal-title":"Nature"},{"key":"2019060412153491000_ref37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nature23884","article-title":"The 4D nucleome project","volume":"549","author":"Dekker","year":"2017","journal-title":"Nature"},{"key":"2019060412153491000_ref38","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1073\/pnas.1505822112","article-title":"Functional organization of the human 4D Nucleome","volume":"112","author":"Chen","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2019060412153491000_ref39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.gde.2005.01.005","article-title":"The key to development: interpreting the histone code?","volume":"15","author":"Margueron","year":"2005","journal-title":"Curr. Opin. Genet. Dev."},{"key":"2019060412153491000_ref40","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.tibs.2017.10.004","article-title":"Histone marks in the \u2018driver\u2019s seat\u2019: functional roles in steering the transcription cycle","volume":"42","author":"Gates","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"2019060412153491000_ref41","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrm.2016.166","article-title":"Variants of core histones and their roles in cell fate decisions, development and cancer","volume":"18","author":"Buschbeck","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2019060412153491000_ref42","doi-asserted-by":"crossref","first-page":"e1001998","DOI":"10.1371\/journal.pbio.1001998","article-title":"Modulation of the maladaptive stress response to manage diseases of protein folding","volume":"12","author":"Roth","year":"2014","journal-title":"PLoS Biol."},{"key":"2019060412153491000_ref43","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1194\/jlr.M072140","article-title":"Histone deacetylase inhibitors correct the cholesterol storage defect in most Niemann\u2013Pick C1 mutant cells","volume":"58","author":"Pipalia","year":"2017","journal-title":"J. Lipid Res."},{"key":"2019060412153491000_ref44","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1111\/febs.12505","article-title":"The potential of histone deacetylase inhibitors in Niemann\u2013Pick type C disease","volume":"280","author":"Maceyka","year":"2013","journal-title":"FEBS J"},{"key":"2019060412153491000_ref45","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s13311-013-0217-2","article-title":"Treatment of Niemann\u2013Pick type C disease by histone deacetylase inhibitors","volume":"10","author":"Helquist","year":"2013","journal-title":"Neurotherapeutics"},{"key":"2019060412153491000_ref46","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1073\/pnas.1014890108","article-title":"Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann\u2013Pick type C1 mutant human fibroblasts","volume":"108","author":"Pipalia","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2019060412153491000_ref47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-4939-7163-3_18","article-title":"Measuring the effect of histone deacetylase inhibitors (HDACi) on the secretion and activity of alpha-1 antitrypsin","volume":"1639","author":"Wang","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"2019060412153491000_ref48","doi-asserted-by":"crossref","first-page":"38265","DOI":"10.1074\/jbc.M112.404707","article-title":"Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of alpha1-antitrypsin deficiency","volume":"287","author":"Bouchecareilh","year":"2012","journal-title":"J. Biol. Chem."},{"key":"2019060412153491000_ref49","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2174\/156652412801318782","article-title":"Proteostasis, an emerging therapeutic paradigm for managing inflammatory airway stress disease","volume":"12","author":"Bouchecareilh","year":"2012","journal-title":"Curr. Mol. Med."},{"key":"2019060412153491000_ref50","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"key":"2019060412153491000_ref51","doi-asserted-by":"crossref","first-page":"15179","DOI":"10.1073\/pnas.261400698","article-title":"Histone deacetylase inhibitors reduce polyglutamine toxicity","volume":"98","author":"McCampbell","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2019060412153491000_ref52","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington\u2019s disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2019060412153491000_ref53","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington\u2019s disease mice","volume":"23","author":"Ferrante","year":"2003","journal-title":"J. Neurosci."},{"key":"2019060412153491000_ref54","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","article-title":"Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington\u2019s disease","volume":"280","author":"Gardian","year":"2005","journal-title":"J. Biol. Chem."},{"key":"2019060412153491000_ref55","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00001756-200303240-00007","article-title":"Inducible PC12 cell model of Huntington\u2019s disease shows toxicity and decreased histone acetylation","volume":"14","author":"Igarashi","year":"2003","journal-title":"Neuroreport"},{"key":"2019060412153491000_ref56","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/hmg\/ddm078","article-title":"Histones associated with downregulated genes are hypo-acetylated in Huntington\u2019s disease models","volume":"16","author":"Sadri-Vakili","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"2019060412153491000_ref57","doi-asserted-by":"crossref","first-page":"976","DOI":"10.2174\/1389450116666150416114514","article-title":"Epigenetics in cystic fibrosis: epigenetic targeting of a genetic disease","volume":"16","author":"Sirinupong","year":"2015","journal-title":"Curr. Drug Targets"},{"key":"2019060412153491000_ref58","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/febs.13061","article-title":"Class IIa HDACs\u2014new insights into their functions in physiology and pathology","volume":"282","author":"Parra","year":"2015","journal-title":"FEBS J."},{"key":"2019060412153491000_ref59","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12272-017-0998-7","article-title":"Therapeutic effects of histone deacetylase inhibitors on kidney disease","volume":"41","author":"Chun","year":"2018","journal-title":"Arch. Pharm. Res."},{"key":"2019060412153491000_ref60","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4137\/BBI.S38427","article-title":"Integrating epigenomics into the understanding of biomedical insight","volume":"10","author":"Han","year":"2016","journal-title":"Bioinform. Biol. Insights"},{"key":"2019060412153491000_ref61","doi-asserted-by":"crossref","DOI":"10.1515\/revneuro-2017-0049","article-title":"Recent studies on cellular and molecular mechanisms in Alzheimer\u2019s disease: focus on epigenetic factors and histone deacetylase","author":"Dubey","year":"2018","journal-title":"Rev. Neurosci."},{"key":"2019060412153491000_ref62","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jcmgh.2017.04.007","article-title":"Epigenetics and liver fibrosis","volume":"4","author":"Moran-Salvador","year":"2017","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"2019060412153491000_ref63","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ymthe.2016.10.004","article-title":"A proof-of-concept for epigenetic therapy of tissue fibrosis: inhibition of liver fibrosis progression by 3-Deazaneplanocin A","volume":"25","author":"Zeybel","year":"2017","journal-title":"Mol. Ther."},{"key":"2019060412153491000_ref64","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.mad.2017.08.008","article-title":"HDAC inhibitors: a new promising drug class in anti-aging research","volume":"166","author":"Pasyukova","year":"2017","journal-title":"Mech. Ageing Dev."},{"key":"2019060412153491000_ref65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40035-017-0089-1","article-title":"The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer\u2019s disease","volume":"6","author":"Yang","year":"2017","journal-title":"Transl. Neurodegener"},{"key":"2019060412153491000_ref66","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.biochi.2016.02.014","article-title":"Valproic acid reduces insulin-resistance, fat deposition and FOXO1-mediated gluconeogenesis in type-2 diabetic rat","volume":"125","author":"Khan","year":"2016","journal-title":"Biochimie"},{"key":"2019060412153491000_ref67","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/acn3.147","article-title":"The promise and perils of HDAC inhibitors in neurodegeneration","volume":"2","author":"Didonna","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"2019060412153491000_ref68","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2174\/156802609788085250","article-title":"Histone deacetylase inhibitors in inflammatory disease","volume":"9","author":"Halili","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"2019060412153491000_ref69","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/ACI.0000000000000029","article-title":"Histone deacetylases and their inhibitors: new implications for asthma and chronic respiratory conditions","volume":"14","author":"Royce","year":"2014","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"2019060412153491000_ref70","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.cell.2007.10.025","article-title":"An adaptable standard for protein export from the endoplasmic reticulum","volume":"131","author":"Wiseman","year":"2007","journal-title":"Cell"},{"key":"2019060412153491000_ref71","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1074\/mcp.M116.064949","article-title":"Quantitative analysis of the proteome response to the histone deacetylase inhibitor (HDACi) vorinostat in Niemann\u2013Pick Type C1 disease","volume":"16","author":"Subramanian","year":"2017","journal-title":"Mol. Cell Proteomics"},{"key":"2019060412153491000_ref72","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nature15729","article-title":"F508 CFTR interactome remodelling promotes rescue of cystic fibrosis","volume":"528","author":"Pankow","year":"2015","journal-title":"Nature"},{"key":"2019060412153491000_ref73","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1021\/ml200136e","article-title":"Potential agents for treating cystic fibrosis: cyclic tetrapeptides that restore trafficking and activity of DeltaF508-CFTR","volume":"2","author":"Hutt","year":"2011","journal-title":"ACS Med. Chem. Lett"},{"key":"2019060412153491000_ref74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nchembio.275","article-title":"Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis","volume":"6","author":"Hutt","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"2019060412153491000_ref75","first-page":"7","article-title":"Histone deacetylase inhibitors: updated studies in various epigenetic-related diseases","volume":"2","author":"Zwergel","year":"2016","journal-title":"J. Clin. Epigenet."},{"key":"2019060412153491000_ref76","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"2019060412153491000_ref77","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40265-015-0388-8","article-title":"Panobinostat: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"2019060412153491000_ref78","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ja.2011.35","article-title":"Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma","volume":"64","author":"VanderMolen","year":"2011","journal-title":"J. Antibiot."},{"key":"2019060412153491000_ref79","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Invest."},{"key":"2019060412153491000_ref80","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12931-017-0705-8","article-title":"Inhibition of histone-deacetylase activity rescues inflammatory cystic fibrosis lung disease by modulating innate and adaptive immune responses","volume":"19","author":"Bodas","year":"2018","journal-title":"Respir. Res."},{"key":"2019060412153491000_ref81","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/ncb2090","article-title":"Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition","volume":"12","author":"Luciani","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"2019060412153491000_ref82","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.biocel.2017.05.002","article-title":"The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis","volume":"88","author":"Bergougnoux","year":"2017","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2019060412153491000_ref83","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/358761a0","article-title":"Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive","volume":"358","author":"Denning","year":"1992","journal-title":"Nature"},{"key":"2019060412153491000_ref84","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells","volume":"92","author":"Marks","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"2019060412153491000_ref85","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1158\/1535-7163.MCT-09-0138","article-title":"The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer","volume":"8","author":"Crisanti","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"2019060412153491000_ref86","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1349-7006.2000.tb00899.x","article-title":"Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells","volume":"91","author":"Murata","year":"2000","journal-title":"Jpn. J. Cancer Res."},{"key":"2019060412153491000_ref87","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1089\/scd.2007.9994","article-title":"Depsipeptide (FK228) preferentially induces apoptosis in BCR\/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis","volume":"16","author":"Okabe","year":"2007","journal-title":"Stem Cells Dev."},{"key":"2019060412153491000_ref88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1479-5876-5-49","article-title":"The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo","volume":"5","author":"Buckley","year":"2007","journal-title":"J. Transl. Med."},{"key":"2019060412153491000_ref89","first-page":"711","article-title":"Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models","volume":"40","author":"Gravina","year":"2012","journal-title":"Int. J. Oncol."},{"key":"2019060412153491000_ref90","doi-asserted-by":"crossref","first-page":"13682","DOI":"10.1074\/jbc.RA118.002607","article-title":"Silencing of the Hsp70-specific nucleotide-exchange factor BAG3 corrects the F508del-CFTR variant by restoring autophagy","volume":"293","author":"Hutt","year":"2018","journal-title":"J. Biol. Chem."},{"key":"2019060412153491000_ref91","doi-asserted-by":"crossref","first-page":"C1734","DOI":"10.1152\/ajpcell.2001.281.5.C1734","article-title":"Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists","volume":"281","author":"Galietta","year":"2001","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2019060412153491000_ref92","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/thoraxjnl-2011-200393","article-title":"Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation","volume":"67","author":"Clancy","year":"2011","journal-title":"Thorax"},{"key":"2019060412153491000_ref93","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/17512433.2017.1378094","article-title":"Lumacaftor\/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation","volume":"10","author":"Bulloch","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"2019060412153491000_ref94","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.15252\/emmm.201607137","article-title":"Orkambi(R) and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue","volume":"9","author":"Molinski","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"2019060412153491000_ref95","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1152\/ajplung.00198.2017","article-title":"Vx-809\/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells","volume":"314","author":"Ruffin","year":"2017","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"2019060412153491000_ref96","first-page":"1","article-title":"Tezacaftor for the treatment of cystic fibrosis","author":"Sala","year":"2018","journal-title":"Expert Rev. Respir. Med"},{"key":"2019060412153491000_ref97","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/ppul.20168","article-title":"Processing of CFTR: traversing the cellular maze\u2014how much CFTR needs to go through to avoid cystic fibrosis?","volume":"39","author":"Amaral","year":"2005","journal-title":"Pediatr. Pulmonol."},{"key":"2019060412153491000_ref98","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/01.mcp.0000141247.22078.46","article-title":"Pharmacologic therapy for stop mutations: how much CFTR activity is enough?","volume":"10","author":"Kerem","year":"2004","journal-title":"Curr. Opin. Pulm. Med."},{"key":"2019060412153491000_ref99","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1158\/1535-7163.MCT-07-0251","article-title":"Histone deacetylase inhibitors selectively suppress expression of HDAC7","volume":"6","author":"Dokmanovic","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"2019060412153491000_ref100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2018.06.017","article-title":"A proteomic variant approach (ProVarA) for personalized medicine of inherited and somatic disease","author":"Hutt","year":"2018","journal-title":"J. Mol. Biol."},{"key":"2019060412153491000_ref101","doi-asserted-by":"crossref","first-page":"13477","DOI":"10.1074\/jbc.RA118.003192","article-title":"Correcting the F508del-CFTR variant by modulating eukaryotic translation initiation factor 3\u2013mediated translation initiation","volume":"293","author":"Hutt","year":"2018","journal-title":"J. Biol. Chem."},{"key":"2019060412153491000_ref102","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1093\/hmg\/ddx367","article-title":"Mutation-specific downregulation of CFTR2 variants by gating potentiators","volume":"26","author":"Avramescu","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"2019060412153491000_ref103","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1159\/000475578","article-title":"Combination of correctors rescues CFTR transmembrane-domain mutants by mitigating their interactions with proteostasis","volume":"41","author":"Lopes-Pacheco","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"2019060412153491000_ref104","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/B978-0-12-805420-8.00007-X","volume-title":"Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging","author":"Thomas","year":"2017"},{"key":"2019060412153491000_ref105","doi-asserted-by":"crossref","first-page":"34264","DOI":"10.1074\/jbc.M112.397307","article-title":"A novel approach to recovery of function of mutant proteins by slowing down translation","volume":"287","author":"Meriin","year":"2012","journal-title":"J. Biol. Chem."},{"key":"2019060412153491000_ref106","doi-asserted-by":"crossref","first-page":"e1002462","DOI":"10.1371\/journal.pbio.1002462","article-title":"Ribosomal stalk protein silencing partially corrects the DeltaF508-CFTR functional expression defect","volume":"14","author":"Veit","year":"2016","journal-title":"PLoS Biol"},{"key":"2019060412153491000_ref107","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1183\/09031936.04.00014804","article-title":"Genotype\/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients","volume":"23","author":"Decaestecker","year":"2004","journal-title":"Eur. Respir. J."},{"key":"2019060412153491000_ref108","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1091\/mbc.e11-05-0396","article-title":"Alteration of CFTR transmembrane span integration by disease-causing mutations","volume":"22","author":"Patrick","year":"2011","journal-title":"Mol. Biol. Cell"},{"key":"2019060412153491000_ref109","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1378\/chest.14-1198","article-title":"Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation","volume":"147","author":"Yousef","year":"2015","journal-title":"Chest"},{"key":"2019060412153491000_ref110","doi-asserted-by":"crossref","first-page":"86581","DOI":"10.1172\/jci.insight.86581","article-title":"Analysis of cystic fibrosis-associated P67L CFTR illustrates barriers to personalized therapeutics for orphan diseases","volume":"1","author":"Sabusap","year":"2016","journal-title":"JCI Insight"},{"key":"2019060412153491000_ref111","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrg.2017.89","article-title":"Prioritizing diversity in human genomics research","volume":"19","author":"Hindorff","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"2019060412153491000_ref112","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2017.02.024","article-title":"Molecular Structure of the human CFTR ion channel","volume":"169","author":"Liu","year":"2017","journal-title":"Cell"}],"container-title":["Human Molecular Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/28\/12\/1982\/28765724\/ddz026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T13:16:12Z","timestamp":1559654172000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hmg\/article\/28\/12\/1982\/5308640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":112,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,2,7]]},"published-print":{"date-parts":[[2019,6,15]]}},"URL":"https:\/\/doi.org\/10.1093\/hmg\/ddz026","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/399451","asserted-by":"object"}]},"ISSN":["0964-6906","1460-2083"],"issn-type":[{"value":"0964-6906","type":"print"},{"value":"1460-2083","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6,15]]},"published":{"date-parts":[[2019,2,7]]}}}